Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene that encodes a tumor-suppressor protein called merlin. NF2 is characterized by formation of multiple schwannomas, meningiomas and ependymomas. Merlin loss-of-function is associated with increased activity of Rac and p21-activated kinases (PAKs) and deregulation of cytoskeletal organization. LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates the actin severing and depolymerizing activity of cofilin. LIMKs also translocate into the nucleus and regulate cell cycle progression. Significantly, LIMKs are overexpressed in several tumor types, including skin, breast, lung, liver and prostate. Here we report that mouse Schwann cells (MSCs) in which merlin function is lost as a result of Nf2 exon2 deletion (Nf2 DEx2 ) exhibited increased levels of LIMK1, LIMK2 and active phospho-Thr508/505-LIMK1/2, as well as phospho-Ser3-cofilin, compared with wild-type normal MSCs. Similarly, levels of LIMK1 and 2 total protein and active phosphorylated forms were elevated in human vestibular schwannomas compared with normal human Schwann cells (SCs). Reintroduction of wild-type NF2 into Nf2 DEx2 MSC reduced LIMK1 and LIMK2 levels. We show that pharmacological inhibition of LIMK with BMS-5 decreased the viability of Nf2 DEx2 MSCs in a dose-dependent manner, but did not affect viability of control MSCs. Similarly, LIMK knockdown decreased viability of Nf2 DEx2 MSCs. The decreased viability of Nf2 DEx2 MSCs was not due to caspase-dependent or -independent apoptosis, but rather due to inhibition of cell cycle progression as evidenced by accumulation of cells in G 2 /M phase. Inhibition of LIMKs arrests cells in early mitosis by decreasing aurora A activation. Our results suggest that LIMKs are potential drug targets for NF2 and tumors associated with merlin deficiency.
INTRODUCTION
Mutations in the tumor-suppressor gene NF2 cause neurofibromatosis type 2 (NF2), an autosomal-dominant disorder with an incidence of about 1 in 25 000 individuals. 1 The characteristic feature of NF2 is the development of bilateral vestibular schwannomas (VSs) that typically cause deafness, facial paralysis and disequilibrium following surgical removal to prevent lifethreatening complications. Frequently, NF2 patients also develop multiple schwannomas in other nerves, as well as meningiomas and ependymomas. 2 Mutations in the NF2 gene are also common in malignant mesothelioma. 3 Currently, the standard treatment for NF2 schwannomas is microsurgery or stereotactic radiosurgery. Unfortunately, limited operability, poor preservation of hearing, diminished functionality of facial nerves and the small risk of radiation-induced malignant transformation later compromise good clinical outcomes. Only a handful of NF2 preclinical and clinical trials are ongoing, all of which utilize existing anti-cancer drugs. 4, 5 The NF2 gene encodes a tumor suppressor called merlin or schwannomin. Merlin regulates a number of processes in Schwann cells (SCs). 6, 7 Normal SCs usually proliferate slowly and adopt a bipolar morphology; however, merlin-deficient human schwannoma cells (HSCs) exhibit abnormalities in proliferation, motility and morphology in vitro. 8 The mechanism of action of merlin remains poorly understood, but appears to involve regulation of surface receptor activity and turnover by modulation of their interactions with the actin cytoskeleton and transduction of downstream signals. 7 A potential pathway through which merlin regulates the actin cytoskeleton involves Cdc42/Rac-p21-activated kinase (PAK)-LIM domain kinase (LIMK)cofilin. [9] [10] [11] Loss of merlin function is associated with elevated levels of active Rac and PAK, suggesting that merlin is a negative regulator of Rac and PAK-dependent pathways. Conversely, PAK phosphorylates and inactivates tumor-suppressor activity of merlin. 12, 13 Work from our laboratory has shown that activation of b1-integrin in normal SCs promotes PAK-dependent phosphorylation of merlin at serine-518 14 . Although PAK has been studied as a potential therapeutic target for NF2, its large number of substrates confounds its usefulness. 15 The LIMK family has two members, LIMK1 and LIMK2, which can be phosphorylated by Cdc42/Rac-PAK1, 2 and 4 at threonine-505/ 508 and converted into active serine/threonine kinases. LIMKs are also regulated by Rho-associated kinases and the myotonic dystrophy kinase-related Cdc42-binding kinase. The major LIMK substrate is the actin depolymerizing and severing protein cofilin/ ADF. 16 LIMK-dependent phosphorylation of cofilin at serine-3 inactivates cofilin and promotes stabilization of the actin cytoskeleton. 17 LIMKs also translocate from the cortical cytoplasm and focal adhesions, where they modulate cell morphology and motility, to the centrosome and nucleus, where they regulate mitosis and cytokinesis. [18] [19] [20] [21] [22] [23] [24] LIMKs interact with aurora A, a serine/threonine kinase involved in centrosome dynamics, spindle assembly and chromosome alignment and segregation during mitosis. 25, 26 Aurora A is found on duplicated centrosomes and mitotic spindle microtubules. During early mitosis, phospho-LIMKs co-localize with g-tubulin in the centrosomes. In metaphase, LIMK1 is found at the spindle poles and later redistributes to the cleavage furrow. LIMK2 is located along the spindle and at the cleavage furrow of post-mitotic cells. LIMK1 is a substrate for, and phosphorylates, aurora A to promote its autophosphorylation at Thr288. 27 LIMK2 is an aurora A substrate and stabilizes it by kinase and scaffolding actions. 28 LIMKs are overexpressed and implicated in various cancers, such as breast, lung, skin, liver and prostate, and several tumor cell lines. [29] [30] [31] [32] Hence, LIMKs are emerging cancer targets; yet, few inhibitors have been identified. 33 We show that the levels of total and phosphorylated LIMK and its phosphorylated substrate are elevated in sporadic VSs compared with normal HSCs. Utilizing Nf2 DEx2 mouse SCs (MSCs) as a cellular model of NF2, we show that pharmacological inhibition or genetic silencing of LIMK significantly reduces proliferation of Nf2 DEx2 MSCs, but does not substantially affect control Nf2 flox2/flox2 MSCs. The decreased proliferation is due to cell cycle arrest in the G 2 /M phase. Pharmacological inhibition of LIMKs with BMS-5 slows mitotic progression by decreasing phosphorylation of cofilin and aurora A. These studies suggest that LIMKs are potential therapeutic targets for NF2 and other merlin-deficient tumors.
RESULTS
LIMK and phospho-cofilin levels are elevated in Nf2 DEx2 MSCs compared with controls Using two complementary techniques, we assessed the levels of LIMK and phospho-Ser3-cofilin in Nf2-deficient (Nf2 DEx2 ) MSC lines developed by in vitro ad-Cre deletion of Nf2 exon2 from Nf2 flox2/flox2 MSCs. 34 By immunostaining Nf2 DEx2 , MSCs were confirmed to be merlin-deficient and expressed the SC marker S100 (Figure 1a ). Merlin-deficient SCs were larger than control Nf2 flox2/flox2 MSCs and had increased levels of F-actin revealed by phalloidin staining. The intensity of LIMK1 and LIMK2 immunofluorescence was higher in Nf2 DEx2 MSCs than in controls and was detected throughout the cell. Consistent with increased LIMK activity, the intensity of phospho-Ser3-cofilin immunofluorescence was also higher in Nf2 DEx2 MSCs than in controls (Figures 1a and b).
We also assessed merlin expression in control Nf2 flox2/flox2 and Nf2 DEx2 MSCs by western blotting using an N-terminal merlin antibody. Merlin was detected in Nf2 flox2/flox2 MSCs but not in Nf2 DEx2 MSCs (Figure 1c ). The status of the Nf2 gene was also confirmed by PCR analysis of DNA and revealed deletion of exon 2 in Nf2 DEx2 as evidenced by a 338-bp band (Figure 1d ). 34 In addition, western blotting confirmed that levels of both LIMK1 and LIMK2 protein were higher in Nf2 DEx2 MSCs than in Nf2 flox2/flox2 MSCs (Figure 1e ). We detected a coordinate increase in the level of phospho-Ser3-cofilin in Nf2 DEx2 MSCs with respect to control consistent with high levels of LIMK activity (Figure 1f ).
Reintroduction of wild-type NF2 normalizes LIMK protein levels
To assess whether elevated LIMK levels were linked to merlin inactivation, we reintroduced a halo-tagged wild-type human NF2 into Nf2 DEx2 MSCs by nucleofection. This method yielded B10% transfection rate, determined by halo-tag fluorescence labeling. Reexpression of merlin in cultured Nf2 DEx2 MSCs generally decreased LIMK1, LIMK2 and phospho-Ser3-cofilin levels (Figures 2a and b). This result supports a relationship between merlin inactivation and increased LIMK expression and activity.
Pharmacological inhibition of LIMK1/2 by BMS-5 or genetic silencing of LIMK1/2 reduces Nf2 DEx2 MSC viability We next sought to determine whether LIMK was a potential drug target for NF2. We tested the efficacy of BMS-5, a highly selective small-molecule inhibitor of LIMK1/2, on reducing phosphorylation of cofilin on Ser3. 35 BMS-5 inhibited cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2 DEx2 MSCs with an IC 50 ofB2 mM (Figures 3a and b ). We next tested the ability of BMS-5 to reduce viability of Nf2 DEx2 MSCs. The 100% viability control was 0.1% dimethyl sulfoxide (DMSO), and a positive cell death control was obtained with 50 mM rapamycin that caused approximately 80% cell death in 24 h. BMS-5 reduced Nf2 DEx2 MSC viability in a dose-dependent manner with an IC 50 of 3.9 mM ( Figure 3c ), but did not significantly reduce the viability of control Nf2 flox2/flox2 MSCs at equivalent BMS-5 concentrations (Figure 3d ). At 10 mM BMS-5, Nf2 DEx2 MSC viability was 40% compared with 83% for controls.
To confirm the validity of LIMK as a drug target, we knocked down LIMK1 and LIMK2 in Nf2 DEx2 MSCs using lentiviral shRNA transduction (Supplementary Figure S1 ). Consistent with the BMS-5 results, LIMK1 and LIMK2 knockdown reduced viability of Nf2 DEx2 MSCs compared with scrambled shRNA controls in a 24-h assay ( Figure 3e ). These results suggest that LIMK inhibition or silencing in merlin-deficient cells reduces their viability either by promoting cell death or hindering proliferation.
Decreased viability of Nf2 DEx2 MSCs in response to BMS-5 or LIMK silencing is independent of apoptosis To determine if BMS-5 promoted Nf2 DEx2 MSC apoptosis, we measured caspase 3/7 activity. We found that BMS-5 did not activate caspase 3/7, whereas the positive control, staurosporine, promoted dose-dependent activation of caspase 3/7 (Figure 5a ). To determine if BMS-5 promoted caspase-independent apoptosis, we analyzed BMS-5-treated Nf2 DEx2 MSCs by flow cytometry using a ratiometric membrane asymmetry probe that detects loss of membrane phospholipid asymmetry associated with apoptosis. We observed only a small increase (3.5%) of apoptotic cells after 7 h of BMS-5 treatment ( Figure 4b ). Consistent with pharmacological LIMK inhibition, knockdown of LIMK1 or LIMK2 was not associated with caspase 3/7 activity increase compared with scrambled shRNA controls examined 24 h after plating ( Figure 4c ). Similarly, caspase-independent apoptosis was not observed in Nf2 DEx2 MSCs transduced with either LIMK1 or LIMK2 shRNA ( Figure 4d ). These results suggest that pharmacological inhibition and genetic silencing of LIMK affect Nf2 DEx2 MSC viability through an apoptosis-independent mechanism.
Pharmacological inhibition of LIMK1/2 by BMS-5 reduces DNA synthesis and cell cycle progression We next assessed the ability of BMS-5 to interfere with proliferation of Nf2 DEx2 MSCs. The cells were incubated with 1 and 2 mM BMS-5 for 24, 48 and 72 h, and cell numbers were measured using crystal violet staining. We observed fewer BMS-5treated Nf2 DEx2 MSCs than DMSO-treated controls (Figure 5a ). In addition, we found that BMS-5 decreased DNA synthesis in Nf2 DEx2 MSCs in a dose-dependent manner (Figure 5b) .
To test the possibility that the decrease in proliferation was a consequence of cell cycle inhibition, we performed flow cytometry analysis of cells stained with propidium iodine (PI). BMS-5 interfered with Nf2 DEx2 MSCs cell cycle progression as evidenced by an increase in the percentage of diploid cells trapped in the G 2 /M phase ( Figure 6a ). We further analyzed the distribution of cells among the cell cycle phases using a BrdU/7AAD assay. There was a significant increase in the number of cells accumulating in the G 2 /M phase in samples treated with 5 mM BMS-5 as compared with vehicle control (20% vs 42%). This was accompanied by a decrease in the number of BMS-5-treated cells in G 1 as compared with control (41% vs 26%). This is consistent with the results obtained by analysis of PI staining (Figures 6b and c) . Overlay of the 7AAD-area histograms clearly demonstrated a significant increase in the G 2 /M population in BMS-5 compared with DMSO-treated cells (Figure 6d ). Furthermore, the increase in the G 2 /M population was accompanied by an increase in the number of cells with higher DNA content, consistent with a polyploidy or multinucleated cell population. There was also a smaller but substantial change in number of cells detected in the S phase of cell cycle in samples treated with BMS-5 as compared with Figure S2 ). These results taken together suggest that inhibition of LIMK activity in Nf2 DEx2 MSCs interferes with progression of the G2/M phase of the cell cycle, thereby decreasing the number of viable Nf2 DEx2 MSCs.
BMS-5 inhibition of LIMK1/2 activity decreases aurora A phosphorylation and causes formation of abnormal mitotic spindles
To identify additional downstream effects of BMS-5 (beyond inhibition of cofilin-Ser3 phosphorylation) that could cause a G 2 /M arrest, we tested the levels of aurora A phosphorylation. Aurora A interacts with both LIMK1 and 2 and is a major regulator of mitotic spindle assembly and chromosomal alignment and segregation. We found that Nf2 DEx2 MSCs treated with increasing concentrations of BMS-5 had a dose-dependent decreased phosphorylation of aurora A at Thr288 (Figures 7a and b) .
We next studied the effect of BMS-5 on the spindle assembly visualizing the mitotic nuclei and spindle machinery by immuno staining. We found that Nf2 DEx2 MSCs had normal spindle assembly and BMS-5-treated Nf2 DEx2 MSCs showed abnormal spindle structure (Figure 8a ). Analyzing the centrosome positioning by immunostaining for centrin-1, we found that BMS-5-treated cells were not able to organize the centrosomes and generally had more than two with different sizes (Figure 8b ). We conducted cell cycle analysis and found that the percentage of cells in late G 2 /M, visualized by positive immunostaining for the mitotic marker phospho-Ser10-histone3, significantly increased from 5 to 17% in the BMS-5-treated Nf2 DEx2 MSCs compared with DMSO controls (Figures 8c and d) . We observed a highly significant decrease in the percentage BMS-5treated Nf2 DEx2 MSCs that advanced to late mitotic phases (anaphase/telophase). Moreover, BMS-5-treated Nf2 DEx2 MSCs had abnormal spindles, and chromosomes did not align at the center as occurs in metaphase (Figures 8a-e ). These results suggest that LIMK inhibition exerts its anti-proliferative effect not only by altering organization of the actin cytoskeleton through inhibition of cofilin phosphorylation but also by decreasing LIMK-dependent activation of aurora A.
LIMK levels are elevated in representative samples of human VS compared with HSCs
To examine the relevance of LIMK inhibition to NF2, we compared LIMK1 and LIMK2 protein and phosphorylation levels in a small number of samples of HSCs from normal individuals and sporadic human VSs. We observed a significant increase (Po0.05 determined using unpaired t-test of HSC vs VS populations, two-tailed) in both the protein and phospho-Thre508 levels of LIMK1 in VSs compared with HSCs (Figures 9a and b) . Similarly, both LIMK2 and phospho-Thr505-LIMK2 levels showed a tendency to be higher in VSs compared with HSCs (Figures 9c and d) . Interestingly, the proportion of phospho-Ser3-cofilin to the total cofilin was higher in VSs than in HSCs (Figure 9e ).
We also measured LIMK protein and phosphorylation levels in a HSC line, HEI-193, developed from a NF2 patient by immortalization with HPV E6-E7 genes. 36 Although the phospho-Thr508/ Thr505 LIMK1/2 antibody recognized multiple bands, the relative intensities of the most prominent phospho-LIMK1/2 (Thr508/ Thr505) bands were also higher in HEI-193 cells than in control HSCs (Figure 9f ).
DISCUSSION
LIMK expression and activity are elevated in merlin-deficient SCs compared with normal SCs Here we document an association between loss of merlin function and increased levels of LIMK1 and LIMK2 expression and activity.
The increased LIMK activity in Nf2-deficient MSCs is consistent with its activation by Cdc42/Rac-PAK1, 2 and 4, 16 which have been well-documented to be increased in schwannomas. 12, 15 Importantly, reintroduction of merlin into Nf2 DEx2 MSCs reduced LIMK and phospho-Ser3-cofilin levels, further supporting an association between loss of merlin function and inactivation of the actin severing and depolymerizing activity of cofilin downstream of activation of the Rac/PAK/LIMK pathway. In agreement with previous studies of HSCs, we found that Nf2 DEx2 MSCs exhibited an abnormal actin cytoskeleton compared with control MSCs. 8 Interestingly, similar cytoskeleton characteristics, indicative of F-actin stabilization, have been reported in C2C12 and HeLa cells overexpressing LIMK. 17, 37 We propose that phosphorylation and inactivation of cofilin downstream of elevated Rac/PAK/LIMK activity could account for the reported increased cell size and abundance of actin filaments observed in Nf2 DEx2 MSCs and HSCs. 38 
Inhibition of LIMK activities causes cell cycle arrest of Nf2 DEx2 MSCs by preventing aurora A activation
We recently demonstrated using BMS-5 that LIMK-dependent phosphorylation of cofilin is necessary for stable alignment of SC processes along sensory neuron axons in culture. 39 Here we showed that BMS-5 decreased Nf2-deficient MSC viability in a dose-dependent manner while having little effect on controls. These results suggest a potential therapeutic window for treatment of schwannomas with LIMK inhibitors. Studies using shRNA knockdown of LIMK1 and LIMK2 in Nf2 DEx2 MSCs confirmed the specificity of BMS-5 on LIMK activity. Intriguingly, during LIMK silencing in Nf2 DEx2 MSCs, we found that these cells did not sustain long-term LIMK knockdown and were able to restore their original expression levels. Thus, we only used cells within their first two passages after puromycin selection. We speculate that Nf2 DEx2 MSCs silence LIMK shRNA by a methylation-dependent mechanism as shown for PAK shRNAs in schwannoma cells. 15 Inhibition of LIMK activity with BMS-5 reduced Nf2 DEx2 MSC viability by arresting them at the M phase of the cell cycle. Others have shown that the localization and activity of LIMK changes during the cell cycle and that cofilin phosphorylation dynamics are necessary for successful cytokinesis. 21, 23, 24 Importantly, LIMK1 knockdown in HeLa cells or treatment with a LIMK-inhibitor peptide resulted in delayed mitotic progression and irregular spindle orientation. 22 These reports support our conclusion that inhibition of LIMK activity with BMS-5 arrested Nf2-deficient cells in the M phase, thereby decreasing the number of cells in S phase and increasing the number of polyploid cells.
The reported interaction and functional cooperation of LIMK1 and 2 with aurora A led us to explore the effect of LIMK inhibition with BMS-5 on aurora A autophosphorylation. 25 In agreement with the observations made with LIMK1 knockdown in PC-3 cells, we found that BMS-5 reduced aurora A phosphorylation at Thr288. 27 It is important to note that BMS-5 does not directly inhibit aurora A kinase activity, because BMS-5 (compound 3 in Ross-Macdonald et al. 35 ) was tested in vitro against a panel of kinases, and aurora A retained 100% activity when tested with 10 mM BMS-5. 35 Interestingly, the abnormal spindle and centrosome organization observed here resembles the abnormal metaphase spindles with multipolar and/or wheel-barrel shape and non-assembled chromosomes observed in a LIMK2 knockdown in SH-EP neuroblastoma cells. 24 The integrity of the mitotic spindle is required for progression from metaphase to anaphase, and any abnormality in the spindle assembly checkpoint delays or hinders the onset of anaphase. Hence, inhibition of LIMK activity by BMS-5 leads to inhibition of aurora A kinase activity, and thus provides a molecular pathway for the G 2 /M block of merlin-deficient SCs treated with BMS-5.
Recently, LIMK has been show to promote tumor neovascularization through the VEGF/p38/MK2/LIMK1/annexin1 pathway. 40 This finding may potentially connect LIMK inhibition with the observed reduction in angiogenesis in vivo following treatment with bevacizumab, which reduces tumor volumes and, in some patients, restores some hearing. 4 Thus, we speculate that inhibition of LIMK might halt tumor progression not only by interfering with cell cycle progression in schwannoma cells but also by inhibiting angiogenesis.
In conclusion, our studies suggest a potential therapeutic target for NF2, the LIMKs, which are recognized substrates of Cdc42/Rac-PAK1,2,4. We show enhanced LIMK expression and activity in merlin-deficient MSCs, as well as VSs, as opposed to controls. Reduction in LIMK activity or protein levels decreases Nf2-deficient MSC viability by arresting cells in the prometaphase stage of the cell cycle in association with decreased activation of aurora A necessary for centrosome and mitotic spindle organization. Future studies addressing whether LIMK inhibition is an effective treatment for schwannomas in mouse models of NF2 are warranted. 
MATERIALS AND METHODS Inhibitors

Antibodies
Antibodies used were purchased from the following sources: phosphocofilin-Ser3 (77G2), merlin (D1D8), phospho-LIMK1(Thr508)/LIMK2(Thr505) (used in cell lines), LIMK1, phospho-Histone3(Ser10) (D2C8), a-tubulin (DM1A), phospho-aurora A(Thr288)(D13A11) and b-actin (8H10D10) from Cell Signaling (Danvers, MA, USA); LIMK1 (clone42) mouse monoclonal Figure 9 . LIMKs are overexpressed in human VSs. Lysed cultured HSCs cultured in 100-mm dishes and homogenized frozen human sporadic VSs were resolved using SDS-PAGE and analyzed using western blot. Quantitation of the western blots was done by densitometry analysis with ImageJ software, normalized to b-actin and is plotted below. Western blots for (a) LIMK1, (b) phospho-Thr508-LIMK1, (c) LIMK2, (d) phospho-Thr505-LIMK2 and (e) phospho-Ser3-cofilin and cofilin. b-actin was used as a loading control. *Po0.05 determined using unpaired t-test of HSC vs VS populations, two-tailed. (f ) HSCs from normal individuals (control) and HEI-193 cells at P43 and P52 were cultured in 60-mm dishes and analyzed using western blotting for phospho-Thr508/505-LIMK1/2. b-actin was used as a loading control.
antibody from BD Biosciences (San Jose, CA, USA); LIMK2, phospho-LIMK1 (pThr-508) and phospho-LIMK2 (pThr-505) rabbit antibodies from Sigma-Aldrich (St Louis, MO, USA); S-100 rabbit antibody from Dako Cytomation (Glostrup, Denmark); cofilin rabbit antibody from Novus Biologicals (Littleton, CO, USA);centrin-1 rabbit antibody from Abcam (Cambridge, MA, USA); aurora A rabbit antibody from Bethyl Laboratories (Montgomery, TX, USA); peroxidase-conjugated goat anti-rabbit IgG from Pierce, Thermo Fisher Scientific (Rockford, IL, USA); and highly cross-adsorbed Alexa Fluor 488 goat anti-rabbit IgG (H þ L) antibody from Invitrogen (Grand Island, NY, USA).
Generation of Nf2 DEx2 MSCs
Nf2 DEx2 MSCs were generated in vitro by transducing Nf2 flox2/flox2 SCs with an Adeno-Cre virus (University of Iowa Gene Transfer Vector Core) as previously described. 41 The Nf2 DEx2 MSCs were used up to passage 20. All protocols are in accordance with the guidelines of and approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International-certified University of Central Florida (UCF) Institutional Animal Care and Use Committee.
HSC cultures
Vials of frozen purified HSCs received from Dr Patrick Wood at the University of Miami School of Medicine (Miami, FL, USA) were thawed and cultured on Corning (Corning Inc. Life Sciences, Tewksbury, MA, USA) dishes coated with 200 mg/ml poly-L-lysine hydrobromide (Sigma-Aldrich) and 50 mg/ml laminin (Invitrogen) containing D10M growth media: DMEM (Gibco, Life Technologies, Grand Island, NY, USA) plus 10% heat-inactivated fetal bovine serum (HyClone, Logan, UT, USA), 2 mM Forskolin (Sigma, St Louis, MO, USA), 0.02 mg/ml pituitary extract (Biomedical Technologies Inc, Stoughton, MA, USA) and 1% penicillin/streptomycin (Gibco). Frozen vials from the stock bank of HSC were prepared by the Life Alliance Organ Recovery Agency at the University of Miami School of Medicine and cannot be traced to the specific donor. HSCs were prepared from 10 cm biopsy of sural nerve/cauda equine from cadaveric adult human donors. Nerve fragments were incubated for several days, dissociated and plated. SCs were purified by immunopanning with NGFR (nerve growth factor receptor) p75 antibodies. Culture purity based on S100 immunostaining was 96-99%. HEI-193 cells were purchased from ATCC (Manassas, VA, USA) and grown in DMEM plus 10% heatinactivated fetal bovine serum and 1% penicillin/streptomycin.
Human schwannoma samples
Frozen specimens of human sporadic VSs with different types of NF2 mutations were procured with patient informed consents at the Ohio State University according to the Institutional Review Board regulations.
Western blot analysis
Cultured cells were lysed in modified RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% sodium dodecyl sulfate with protease inhibitor cocktail and phosphatase inhibitor cocktails 2 and 3; Sigma-Aldrich). VS specimens (0.1-0.2 g) were homogenated in 900 ml of modified RIPA buffer with 25-30 strokes in a Wheaton Micro Tissue Grinder glass set no. 528 (Wheaton Scientific, Millville, NJ, USA) on ice. Lysates were rotated for 10 min at 4 1C and centrifuged for 10 min at 4 1C, 15 000 r.p.m. Protein concentration was determined by DC Assay (Bio-Rad, Hercules, CA, USA), and 10-20 mg of protein in lamelli buffer was resolved in 10% or 4-20% polyacrylamide gels (Pierce/ Thermo Fisher Scientific), transferred to polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA, USA) and analyzed using western blotting with anti-LIMK1, (1:500) from BD (San Jose, CA, USA) for human samples and (1:500) from Cell Signaling for mouse samples, LIMK2 (1:500), P-cofilin-Ser3 (1:1500), cofilin (1:70 000), merlin (1:500), S-100 (1:300), P-LIMK1-Thr508 (1:1000), P-LIMK2-Thr505 (1:1000) and P-LIMK1(Thr508)/LIMK2(Thr505) (1:200) used in mouse and HEI-193 cell lines, P-aurora (1:1000), aurora A (1:500) and b-actin (1:15 000), followed by corresponding secondary antibodies (1:20 000). Western blots were quantified by densitometry using NIH ImageJ software. Intensities were normalized to b-actin-loading controls.
LIMK1 and LIMK2 knockdown in Nf2 DEx2 MSCs
Nf2 DEx2 MSCs were plated onto poly-L-lysine-coated (200 mg/ml) six-well dishes, cultured at 37 1C, 7% CO 2 , in medium containing DMEM/F12 (Invitrogen/Life Technologies, Grand Island, NY, USA) plus N2 supplement (Invitrogen, Burlington, ON, Canada) and 1% penicillin/streptomycin. When cultures reached 40% confluence, lentiviral transduction particles were added at five multiplicity of infection in growth medium plus 8 mg/ml hexadimethrine bromide (Sigma). MISSION shRNA lentiviral particles for mouse gene silencing were from Sigma-Aldrich. LIMK1 clone IDs: NM_010717.1-1546s1c1 (named construct no. 44); NM_010717.1-1414s1c1 (no. 47) and LIMK2 clone IDs: NM_010718.1-1409s1c1 (no. 73) and NM_010718.3-827s21c1 (no. 95). Negative control was pLKO.1-puro nonmammalian shRNA (SHC002V). Optimum multiplicity of infection determined empirically with pLKO.1-puro-CMV-TurboGFP transduction lentiviral particle (SHC003V) titer. After 18-20 h, infection medium was replaced with fresh medium for 24 h and subsequently replaced with growth medium containing 1 mg/ml puromycin (Sigma-Aldrich) to select transduced cells. The puromycin concentration was determined by plotting a toxicity curve.
Reintroduction of NF2 into Nf2 DEx2 MSCs
To reintroduce merlin into Nf2 DEx2 MSCs, 1.5-2 million cells were resuspended in 100 ml of basic nucleofector solution for mammalian glial cells with supplements (Lonza, Cologne, Germany) plus 1 mg of pFC15K HaloTagCMVd1-NF2 using an Amaxa Nucleofector II device and Program A-033. One milliliter of warm growth medium was added, and 50 ml of cell suspension was seeded on coated 11-mm round German glass coverslips (Carolina Biology, Burlington, NC, USA) containing 100 ml of equilibrated growth medium and incubated 40 h at 37 1C, 7% CO 2, before analysis.
Immunofluorescence
Cells were plated on coated German glass coverslips and immunostained as previously described. 41 Labeling of Halo-Tag-NF2-transfected cells was done in vivo with HaloTag TMR Ligand (Promega, Madison, WI, USA) following the manufacturer's rapid labeling protocol. Confocal images were acquired with a Zeiss (Carl Zeiss MicroImaging Inc., Thornwood, NY, USA) LSM710 microscope with three spectral detection channels, five laser lines-458, 488, 514, 543 and 633 nm, FL filter set 49 DAPI (4',6-diamidino-2phenylindole), EX G365 shift free, FL filter set 43 CY 3 shift free, FL filter set 38 Endow GFP, shift free, Plan-Apochromat Â 63/1.40 oil DIC M27 and EC Plan-Neofluar Â 40/1.3 DIC WD ¼ 0.21 M27 objective lenses on an AxioObserver Z1 Stand (Carl Zeiss MicroImaging Inc.) and ZEN2009 software (Carl Zeiss MicroImaging Inc.). Fluorescence was collected from a single plane on separate channels maintaining the same acquisition parameters for each labeled protein. Images from each experiment were processed identically with ZEN2011 software (Carl Zeiss MicroImaging Inc.). For spindle images, Z-stacks were collected with the Â 63 oil objective and 3.5 zoom factor. Two-dimensional images were obtained by median filter and maximum intensity projection with ZEN2011.
Cell viability assay
Cell viability was assessed by CellTiter-Fluor assay (Promega) following the manufacturer's specifications. Cells were seeded in 384-well format, centrifuged 1 min at 500 r.p.m. and incubated at 37 1C, 7% CO 2 . After cell attachment (2.5-3.5 h), 5 ml/well of compound/vehicle solution was added and plates were quick spinned and incubated for 24 h. Fluorescence was measured with a Synergy H1 Hybrid plate reader (BioTek, Winooski, VT, USA).
Caspase activity assay
Caspase activity was assessed by the Apo-ONE homogeneous caspase 3/7 assay (Promega) following the manufacturer's specifications. Fluorescence was measured with a plate reader.
Membrane asymmetry assay
Cell membrane asymmetry was measured with the Violet Ratiometric Membrane Asymmetry Probe/Dead Cell Apoptosis Kit (Invitrogen/Life Technologies). Cells were seeded in 200 mg/ml poly-L-lysine-coated six-well plates and incubated with BMS-5/vehicle for 24 h. Cell were harvested and assayed following the manufacturer's instructions. Samples were analyzed on a BD Canto-II (Becton Dickinson and Co, Franklin Lakes, NJ, USA) flowcytometer setting excitation and collection emission wavelength recommended by the manufacturer. The ratio parameter was established using BD FACSDiva 6.1.3 software as recommended by the manufacturer.
Proliferation assays
Cell proliferation was studied with two different techniques. Nf2 DEx2 MSCs were seeded in a 24-well format and had cell numbers assessed with the Crystal Violet Assay as previously described. 42 Absorbance at 595 nm was measured with a mQuant plate reader (BioTek).
Rate of DNA synthesis was evaluated at 24 h with the Click-iT EdU Microplate Assay (Invitrogen/Life Technologies). The assay was carried out in 96-and 384-well plate formats following the manufacturer's instructions without the Amplex UltraRed amplification steps. 4',6-Diamidino-2phenylindole stain was included in the wash after the reaction cocktail incubation step. Oregon green-488 and 4',6-diamidino-2-phenylindole fluorescence was quantified by a plate reader.
Cell cycle analysis
The cell cycle was analyzed by flow cytometry with PI staining and BrdU/ 7AAD. Ethanol-fixed cells (10 6 ) were PI stained using 500 ml PI/RNase staining buffer (Beckton Dickinson). Samples were examined on a BD Canto-II flow cytometer, and histograms were analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA). For each sample, 10 000 events were collected.
The BrdU/7AAD assay kit was from Beckton Dickinson. Cells were seeded in six-well plates and treated with inhibitor/vehicle overnight. Next day, cultures were incubated with 10 mM BrdU for 3 h, and the assay was performed according to the manufacturer's instruction. Samples were analyzed with a BD Canto-II flow cytometer using the BD FACSDiva 6.1.3 software. FlowJo software (Tree Star, Inc, Ashland, OR, USA) was used for analysis of acquired data.
Statistical analysis
GraphPad Prism version 5.0 for Windows (GraphPad, La Jolla, CA, USA) was used for statistical analysis and graph generation of experimental data from three independent experiments. Dose-response experiments were analyzed by nonlinear regression (four parameters). Statistical analysis is indicated for each experiment.
